Amphastar Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $30.3M | $6.4M | $17.4M | $31.0M | $25.3M | $40.4M | $37.9M | $43.2M |
| Depreciation & Amortization | $14.3M | — | $14.1M | $14.6M | — | $13.4M | $13.1M | $9.7M |
| Depreciation | — | $8.1M | — | — | $7.4M | — | — | $6.8M |
| Amortization | — | $6.3M | — | — | $6.2M | — | — | $6.2M |
| Stock-Based Compensation | — | $9.3M | — | — | $8.4M | — | — | $7.4M |
| Net Cash from Operating Activities | $51.3M | $47.8M | $52.6M | $35.6M | $35.1M | $60.0M | $69.1M | $55.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $8.6M | $9.5M | $5.3M | $10.6M | $10.7M | $13.8M | $6.0M | $8.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-16.7M | — | — | $10.5M | — | — | $15.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $29.5M | — | — | $11.0M | — | — | — |
| Net Cash from Financing Activities | — | $-30.2M | — | — | $-14.5M | — | — | $-13.6M |
| Net Change in Cash | — | $762.0K | — | — | $31.2M | — | — | $56.9M |
| Free Cash Flow | $42.7M | $38.3M | $47.2M | $25.0M | $24.4M | $46.2M | $63.1M | $46.5M |